Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Scientific Reports|February 22, 2023
Investigation of SAMD1 ablation in miceBruce Campbell, Lisa M Weber, Sandra J Engle, et al.Bioorganic & Medicinal Chemistry Letters|January 30, 2016
Discovery of spirocyclic proline tryptophan hydroxylase-1 inhibitorsDaniel R Goldberg, Stéphane De Lombaert, Robert Aiello, et al.Bioorganic & Medicinal Chemistry Letters|May 6, 2016
Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitorsDaniel R Goldberg, Stéphane De Lombaert, Robert Aiello, et al.The International Journal of Artificial Organs|April 20, 2022
Protocol-based anticoagulation management for mechanical circulatory support patients can be safe and efficientSarah E Birk, Amanda Ingemi, Patricia Bourassa, et al.Bioorganic & Medicinal Chemistry Letters|January 3, 2017
Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitorsDaniel R Goldberg, Stéphane De Lombaert, Robert Aiello, et al.NAR Cancer|July 28, 2021
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicitySophia Gayle, Robert Aiello, Nalin Leelatian, et al.NAR Cancer|December 10, 2021
Correction to 'Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity'Sophia Gayle, Robert Aiello, Nalin Leelatian, et al.Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.Pageof 1